This is a phase II multi-center, open-label study to evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.
To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.